SCHEDULE: Saturn V Capital Management Reports Stake in Monopar Therapeutics

Saturn V Capital Management LP and Xiaoying Tian have reported beneficial ownership of 313,384 shares, representing 4.7% of Monopar Therapeutics' common stock.

Summary

• Saturn V Capital Management LP, acting as investment manager for various clients, and Xiaoying Tian, Managing Member of its general partner, have filed an amended Schedule 13G.
• The filing reports beneficial ownership of 313,384 shares of Monopar Therapeutics' common stock.
• This holding represents approximately 4.7% of the total outstanding shares.
• The shares are held by pooled investment vehicles and managed accounts (Clients) for which Saturn V Capital Management LP acts as the investment manager.
• Neither Saturn V Capital Management LP nor Xiaoying Tian claims beneficial ownership of the shares held by the Clients, but they possess the power to vote and direct the disposition of these shares.
• The filing is based on Monopar Therapeutics' outstanding shares as of April 30, 2026, as reported in their Form 10-Q filed on May 14, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without indicating a significant shift in investment strategy or company performance.

Positives

• Increased transparency regarding significant shareholding by Saturn V Capital Management LP and Xiaoying Tian.
• The filing indicates a substantial, though not controlling, stake in Monopar Therapeutics.

Negatives

• The filing does not provide details on the investment strategy or rationale behind acquiring this stake.
• The beneficial ownership is disclaimed by the reporting persons, indicating they manage the shares on behalf of others.

Risks

• Potential for future changes in beneficial ownership by Saturn V Capital Management LP, which could impact share price.
• The reliance on a Form 10-Q filed on May 14, 2026, for outstanding share count means the percentage may not reflect the most current data.
• The disclaimer of beneficial ownership by Saturn V Capital Management LP and Xiaoying Tian could obscure the ultimate beneficial owners.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Monopar Therapeutics. It solely reports on the beneficial ownership of Saturn V Capital Management LP and Xiaoying Tian.

Management Comments

• Saturn V Capital Management LP acts as the investment manager of certain pooled investment vehicles and managed accounts (collectively the "Clients") in which such shares referred to above are held. As a result, Saturn V Capital Management LP possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by the Clients.
• No Client holds or beneficially owns five percent or more of the outstanding shares of the Issuer. Saturn V Capital Management LP disclaims beneficial ownership of any of the shares held by the Clients.
• Ms. Tian is the Managing Member of SVCM GP LLC, the general partner of Saturn V Capital Management LP, the Investment Manager of the Clients. As a result, Ms. Tian possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by the Clients. Ms. Tian disclaims beneficial ownership of any of the shares held by the Clients.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing the 5% beneficial ownership threshold. This filing indicates Saturn V Capital Management LP's interest in Monopar Therapeutics, a biotechnology company, aligning with typical investment patterns in the sector.

Stakeholder Impact

• Shareholders: May observe increased trading activity or interest in Monopar Therapeutics due to the reporting of a significant stake by an investment manager.
• Management of Monopar Therapeutics: Will be aware of Saturn V Capital Management LP's holdings and potential influence.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Saturn V Capital Management LP and Xiaoying Tian will continue to manage the shares on behalf of their clients.
• Monopar Therapeutics will continue its operations as disclosed in its other SEC filings.

Key Dates

Keywords

Monopar Therapeutics, Schedule 13G, Beneficial Ownership, Saturn V Capital Management, Investment Management, Common Stock, SEC Filing, Xiaoying Tian